Hypertension Clinical Trials

Find Hypertension Clinical Trials Near You

Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults aged 18 years or older

• Diagnosis of ocular hypertension or open-angle glaucoma

• Eye examination within the past year

• For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma

• Best-corrected visual acuity of 20/100 or better

• Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)

• Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)

Locations
United States
Indiana
Indiana Universtiy School of Optometry
RECRUITING
Bloomington
Contact Information
Primary
Brett J King, OD
kingbrj@iu.edu
(812) 855-1344
Time Frame
Start Date: 2026-06-05
Estimated Completion Date: 2028-06
Participants
Target number of participants: 50
Treatments
Active_comparator: Netarsudil (Rhopressa)
Participants will receive netarsudil ophthalmic solution administered as one drop in the study eye once daily in the evening for approximately 14 days.
Placebo_comparator: Placebo (Artificial Tears)
Participants will receive artificial tears administered as one drop in the study eye once daily in the evening for approximately 14 days.
Sponsors
Collaborators: Alcon Research
Leads: Indiana University

This content was sourced from clinicaltrials.gov